Methotrexate ever pharma

Package leaflet: Information for the user

Methotrexate EVER Pharma, 7.5 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 10 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 12.5 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 15 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 17.5 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 20 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 22.5 mg, solution for injection in pre-filled syringe
Methotrexate EVER Pharma, 25 mg, solution for injection in pre-filled syringe
Methotrexatum
Please read all of this leaflet carefully before using this medicine because it contains important information for you.

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm them even if their symptoms are the same.
• If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist. See section 4.

Contents of the leaflet

1. What Methotrexate EVER Pharma is and what it is used for
2. Important information before using Methotrexate EVER Pharma
3. How to use Methotrexate EVER Pharma
4. Possible side effects
5. How to store Methotrexate EVER Pharma
6. Contents of the pack and other information

1. What Methotrexate EVER Pharma is and what it is used for

Methotrexate EVER Pharma contains the active substance methotrexate, which works by:

• reducing inflammation or swelling, and
• reducing the activity of the immune system (the body's defence mechanism). Excessive immune system activity is associated with inflammatory diseases.

Methotrexate EVER Pharma is used to treat:

• severe, active rheumatoid arthritis in adults. Active rheumatoid arthritis is an inflammatory disease affecting the joints;
• severe, active juvenile idiopathic arthritis affecting five or more joints (this condition is therefore called polyarticular) in patients who have not responded adequately to non-steroidal anti-inflammatory drugs (NSAIDs);
• severe psoriasis that is resistant to treatment, and severe psoriatic arthritis in adults;

2. Information before using Methotrexate EVER Pharma

When not to use Methotrexate EVER Pharma

• if the patient is allergic to methotrexate or any of the other ingredients of this medicine (listed in section 6)
• if the patient has severe or active infection
• if the patient has oral mucositis or gastrointestinal ulceration
• if the patient has severe kidney disease (the physician will assess whether kidney disease is severe)
• if the patient has severe liver disease (the physician will assess whether liver disease is severe)
• if the patient has a blood disorder
• if the patient has immune system disorders
• if the patient consumes excessive amounts of alcohol, has alcoholic liver disease, or another chronic liver disease
• if the patient is pregnant or breastfeeding (see section "Pregnancy, breastfeeding and fertility")
• if the patient is simultaneously receiving vaccines containing live microorganisms.

Warnings and precautions
Important warning regarding dosing of Methotrexate EVER Pharma:
Methotrexate EVER Pharma, used in the treatment of rheumatic diseases or skin disorders,
must be administered once weekly only. Dosing errors during methotrexate therapy
can lead to severe adverse reactions, including death.
Please read section 3 of this leaflet carefully.
If you have any questions, consult your doctor or pharmacist before taking this
medicine.
Before starting treatment with Methotrexate EVER Pharma, discuss with your doctor if:

• the patient has diabetes and is treated with insulin
• the patient has inactive, chronic infections (e.g. tuberculosis, hepatitis B or C, shingles)
• the patient has or has previously had kidney or liver disease
• the patient has lung function disorders
• if the patient is significantly overweight
• if the patient has fluid accumulation in the abdominal cavity or in the space between the lungs and chest wall (ascites, pleural effusion)
• the patient is dehydrated or has conditions leading to dehydration (e.g. vomiting, diarrhoea, oral mucositis).

If the patient, their partner, or caregiver notice new onset or worsening of neurological symptoms, including general muscle weakness, visual disturbances, changes in thinking, memory, and orientation leading to disorientation and personality changes, contact a doctor immediately, as these may be signs of a very rare but serious brain infection called progressive multifocal leukoencephalopathy (PML).
Methotrexate temporarily affects sperm and ovum production. Methotrexate may cause miscarriage and lead to severe congenital malformations. Women should avoid becoming pregnant during treatment with methotrexate and for at least six months after treatment ends. Men should avoid fathering a child during treatment with methotrexate and for at least three months after treatment ends. See also section "Pregnancy, breastfeeding and fertility".
During treatment with Methotrexate EVER Pharma, radiation-induced dermatitis (radiation recall dermatitis) or sunburn may recur.
Exposure to ultraviolet radiation during therapy with Methotrexate EVER Pharma may exacerbate skin lesions associated with psoriasis.
Cases of acute pulmonary haemorrhage have been reported in patients with underlying rheumatological disease during methotrexate therapy. If the patient develops haemoptysis (coughing up blood-stained sputum), seek immediate medical advice.
Diarrhoea may occur as an adverse effect of Methotrexate EVER Pharma, which may require discontinuation of treatment. If diarrhoea occurs, consult your doctor.
Lymphadenopathy (swollen lymph nodes, lymphoma) may occur in patients receiving low-dose methotrexate. In such cases, treatment should be discontinued.

Recommended monitoring and precautions
Severe adverse reactions may occur even after administration of low doses of methotrexate. To detect these reactions early, the physician must perform regular monitoring and laboratory tests.

Before starting treatment:
Before initiating therapy, the physician will recommend blood tests to check whether blood cell counts are sufficient for treatment. The physician will also recommend blood tests to assess liver function and to determine whether hepatitis is present. Additionally, blood tests will be performed to measure serum albumin levels (a blood protein), degree of liver inflammation (liver infection), and kidney function. The physician may also decide to perform further liver tests, some of which may be imaging tests of the liver, while others may require a small liver tissue sample for more detailed examination. The physician may also check for tuberculosis and recommend a chest X-ray or lung function tests.

During treatment:
The physician may recommend the following tests:

• examination of the mouth and throat to check for mucosal changes such as inflammation or ulceration
• blood tests/full blood count to determine blood cell counts and serum methotrexate levels
• blood tests to monitor liver function
• imaging tests to assess liver status
• liver biopsy (taking a small tissue sample from the liver for detailed examination)
• blood tests to monitor kidney function
• monitoring of the respiratory tract and, if necessary, lung function tests

It is very important that the patient attends all scheduled blood tests.
If any of these test results are abnormal, the physician will adjust the treatment accordingly.

Children, adolescents and elderly patients
The use of this medicine is not recommended in children under 3 years of age due to insufficient experience with the drug in this age group.
During treatment with Methotrexate EVER Pharma, children, adolescents, and elderly patients receiving methotrexate should remain under close medical supervision to detect any adverse reactions as early as possible.
In elderly patients, a relatively low dose of methotrexate should be used due to impaired liver and kidney function and reduced folate reserves.

Methotrexate EVER Pharma and other medicines
Inform your doctor or pharmacist about all medicines currently used or recently used, including those obtained without a prescription, herbal remedies, and dietary supplements such as vitamins.
It is particularly important to inform your doctor about the use of:

• non-steroidal anti-inflammatory drugs or salicylates (medicines used to treat pain and/or inflammation, such as acetylsalicylic acid, diclofenac, and ibuprofen)
• azathioprine (a medicine used to prevent organ transplant rejection)
• retinoids (medicines used to treat psoriasis and other skin diseases)
• metamizole (a medicine used to reduce pain and fever)
• other medicines used for rheumatoid arthritis or psoriasis, such as leflunomide, sulfasalazine (also used to treat ulcerative colitis), penicillamine, or cyclosporine
• anticonvulsants (medicines used to prevent epileptic seizures), such as phenytoin, valproate, or carbamazepine
• antineoplastic agents, such as mercaptopurine or fluorouracil
• barbiturates (sedative drugs administered by injection)
• sedatives
• p-aminobenzoic acid (a medicine used to treat skin diseases)
• hydroxychloroquine (a medicine used to prevent and treat malaria)
• oral contraceptives
• probenecid (a medicine used to treat gout)
• antibiotics and medicines used for infections, such as tetracyclines, chloramphenicol, non-absorbable broad-spectrum antibiotics, trimethoprim with sulfamethoxazole, penicillin, glycopeptides, sulfonamides, ciprofloxacin, and cephalothin. Penicillins may reduce methotrexate excretion, potentially increasing the frequency of adverse reactions
• pyrimethamine (a medicine used to prevent and treat malaria)
• folic acid-containing medicines and vitamin preparations
• proton pump inhibitors (medicines that reduce gastric acid production, used to treat severe heartburn or ulcers), such as omeprazole or pantoprazole
• theophylline (a medicine used to treat asthma)
• nitrous oxide (a gas used for general anaesthesia)
• any live vaccines (these should be avoided), such as measles, mumps, or yellow fever vaccines
• cholestyramine (used to reduce blood cholesterol levels)

Methotrexate EVER Pharma, alcohol and drinking
During treatment with Methotrexate EVER Pharma, alcohol should not be consumed. Also avoid excessive intake of coffee, caffeine-containing beverages, and black tea, as these may intensify adverse effects or affect the efficacy of Methotrexate EVER Pharma.
During treatment with Methotrexate EVER Pharma, drink plenty of fluids, as dehydration (reduced body water) may enhance the toxic effects of Methotrexate EVER Pharma.

Pregnancy, breastfeeding and fertility
If the patient is pregnant or breastfeeding, suspects she may be pregnant, or plans to become pregnant, she should consult her doctor or pharmacist before using this medicine.

Pregnancy
Methotrexate EVER Pharma must not be used if the patient is pregnant or planning pregnancy. Methotrexate may cause congenital malformations, harm the unborn child, or cause miscarriage. It may cause malformations of the skull, face, heart, blood vessels, brain, and limbs. Therefore, it is very important that methotrexate is not used in pregnant women or women planning pregnancy. In women of childbearing potential, pregnancy must be definitively excluded, e.g. by performing a pregnancy test before starting treatment. The patient should avoid becoming pregnant during methotrexate treatment and for at least 6 months after treatment ends. During this time, effective contraception methods must be used (see also section "Warnings and precautions").
If a woman becomes pregnant during treatment or suspects she may be pregnant, she should contact her doctor immediately. The doctor will advise her on the risks to the foetus associated with the treatment.
If a patient plans pregnancy, the treating physician may refer her for a specialist consultation before planned treatment initiation.

Breastfeeding
Breastfeeding should not be performed during treatment, as methotrexate passes into breast milk.
If the treating physician considers methotrexate treatment absolutely necessary at this time, breastfeeding must be discontinued.

Male fertility
Available data do not indicate an increased risk of congenital malformations or miscarriage when the father uses methotrexate at doses below 30 mg per week. However, the risk cannot be completely excluded. Methotrexate may have genotoxic effects, meaning it may cause genetic changes. Methotrexate may affect sperm production, potentially leading to congenital malformations. Therefore, patients receiving methotrexate should avoid fathering a child or donating sperm during treatment and for at least 3 months after treatment ends.

Driving and operating machinery
During treatment with Methotrexate EVER Pharma, adverse effects on the central nervous system such as fatigue and dizziness may occur, which may affect the ability to drive or operate machinery. If the patient experiences fatigue or dizziness, they should not drive or operate machinery.

Methotrexate EVER Pharma contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per pre-filled syringe, meaning the medicine is considered "sodium-free".

3. How to use Methotrexate EVER Pharma

Important warning regarding dosing of Methotrexate EVER Pharma (methotrexate)
In the treatment of rheumatoid arthritis, active juvenile idiopathic arthritis, and psoriasis,
Methotrexate EVER Pharma must be used once weekly only.
Taking more than the prescribed amount of Methotrexate EVER Pharma may result in death.
Please read section 3 of this leaflet carefully. If you have any questions, consult your doctor or
pharmacist before taking this medicine.
This medicine should always be used exactly as prescribed by your doctor. If in doubt, consult your
doctor or pharmacist.
Methotrexate EVER Pharma is administered once a week only. Together with your doctor, choose
an appropriate day of the week for the injection.
Improper use of Methotrexate EVER Pharma may lead to severe adverse reactions, which may be
fatal.

Recommended dosage:
Dosing in patients with rheumatoid arthritis
The recommended initial dose is 7.5 mg of methotrexate once weekly.
If the initial dose is not effective and the patient tolerates the medicine well, the doctor may
increase the dose by 2.5 mg per week. The average weekly dose of methotrexate is 15–20 mg.
Generally, a weekly dose exceeding 25 mg should not be used. Once the desired therapeutic
effect has been achieved, your doctor may gradually reduce the dose of Methotrexate EVER
Pharma to the lowest effective maintenance dose.
The expected response to treatment usually occurs after 4–8 weeks. After discontinuation of
Methotrexate EVER Pharma, symptoms may return.

Use in children and adolescents (aged 3 years and older) with polyarticular forms of juvenile
idiopathic arthritis
Your doctor will calculate the required dose based on the child's body surface area (m²). The dose is
expressed as mg/m².
Use in children under 3 years of age is not recommended due to insufficient experience in this
age group.

Adults with severe psoriasis or psoriatic arthritis
Your doctor will administer a single test dose of 2.5–5 mg to assess possible toxic effects. If the test
dose is well tolerated, treatment will continue one week later with a dose of approximately 7.5 mg
(applicable to an adult with an average body weight of 70 kg). Generally, a weekly dose exceeding
25 mg should not be used. Once the desired therapeutic effect has been achieved, your doctor may
gradually reduce the dose of Methotrexate EVER Pharma to the lowest effective maintenance dose.
The expected response to treatment usually occurs after 2–6 weeks. Depending on the severity of
symptoms and blood and urine test results, treatment should be continued or discontinued.

In elderly patients, the dose should be reduced due to age-related decline in liver and kidney
function and reduced folic acid stores.

Method of administration and duration of treatment
Methotrexate EVER Pharma is administered by subcutaneous injection. The medicine may only be
used by subcutaneous injection once weekly. It is recommended to administer Methotrexate EVER
Pharma injections on the same day each week.

At the beginning of treatment, Methotrexate EVER Pharma may be administered by healthcare
professionals. However, your doctor may decide that you are able to self-administer the injection.
You will receive appropriate training in this regard. Never attempt self-injection without prior
training.

The duration of treatment is determined by your doctor. Long-term treatment with Methotrexate
EVER Pharma is required for rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, and
psoriatic arthritis.

How to self-administer Methotrexate EVER Pharma injection
If you have difficulty handling the syringe, consult your doctor or pharmacist.
Do not attempt self-injection unless you have been properly trained in how to do so. If you are
unsure about what to do, contact your doctor or nurse immediately.

Before self-administering Methotrexate EVER Pharma injection

• Check the expiry date of the medicine. Do not use the medicine after the expiry date.
• Check whether the syringe is damaged and whether the solution inside is a clear, yellowish liquid. If not, use another syringe.
• Check whether there is redness, skin discoloration, swelling, leakage, or persistent pain at the site of the previous injection. If such symptoms are present, consult your doctor or nurse.
• Choose the injection site. The injection site should be changed each time.

Instructions for self-administering Methotrexate EVER Pharma injection

1. Open the package. Ensure that the packaging is intact.
2. Place the syringe and needle with protective cap on a clean surface.
3. Wash your hands thoroughly with soap and water.
4. Sit or lie down in a relaxed, comfortable position. Ensure that you can see the area of skin where the injection will be administered. The best injection sites are the skin of the anterior-lateral abdominal wall or the front of the thigh.

5. The pre-filled syringe is ready to use. Inspect the syringe for visible defects (or cracks). Examine the solution. A yellowish liquid should be visible. A small air bubble may be visible in the solution, which will not affect the injection and does not pose a risk to the patient. Do not attempt to remove the air bubble before injection – this may result in loss of part of the medicine.

The pre-filled syringe of Methotrexate EVER Pharma is equipped with a needle safety system
designed to prevent needlestick injury after use. The following instructions apply to pre-filled
syringes equipped with this system and may differ from instructions for other injection systems.

6. Holding the syringe barrel with one hand, remove the protective cap by pulling it straight off to avoid bending the needle. Be careful not to touch the needle with your fingers to maintain sterility.

7. With two fingers, pinch the skin to create a skin fold. Creating a skin fold will ensure delivery of the active substance into the subcutaneous fatty tissue. Quickly insert the needle into the skin at the appropriate angle (45° to 90°) and press the plunger all the way down. Visually check whether any solution remains in the syringe. If liquid remains in the syringe,

this means that the full dose was not properly administered, and you should consult your doctor.

8. When the plunger is fully depressed, the needle will be safely retracted. Only now should you release the skin fold.

9. Press a swab against the injection site. Do not rub the injection site, as this may cause irritation.
10. Immediately dispose of the syringe in a sharps container. Close the container tightly and store it out of reach of children. If accidental contact with methotrexate occurs on the skin or soft tissues, rinse the area thoroughly with plenty of water.

Women who are pregnant or planning to become pregnant should not handle Methotrexate EVER
Pharma.
The duration of treatment is determined by your doctor. Long-term treatment with Methotrexate
EVER Pharma is required for rheumatoid arthritis, juvenile idiopathic arthritis, psoriasis, and
psoriatic arthritis.
If you feel that the effect of Methotrexate EVER Pharma is too strong or too weak, consult your
doctor or pharmacist.

Taking more than the recommended dose of Methotrexate EVER Pharma
Use only the dose prescribed by your doctor. Do not change the dose without medical advice.
If you suspect that you have taken more Methotrexate EVER Pharma than prescribed, contact your
doctor or the nearest hospital emergency department immediately. Patients visiting a doctor or
hospital should bring the medicine packaging and leaflet with them.
Methotrexate overdose may cause severe toxic reactions. Symptoms of overdose may include easy
bruising or bleeding, unexplained weakness, mouth sores, nausea, vomiting, black or bloody stools,
coughing up blood or vomiting material resembling coffee grounds, and reduced urine output. See
also section 4.

Missed dose of Methotrexate EVER Pharma
Do not take a double dose to make up for a missed dose. Consult your doctor for advice.

Stopping Methotrexate EVER Pharma treatment
Do not stop or discontinue treatment with Methotrexate EVER Pharma without consulting your
doctor. If you suspect severe adverse reactions, seek immediate medical advice.

If you have any further questions about the use of this medicine, consult your doctor or
pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone experiences them.
The frequency and severity of adverse reactions depend on the dose and frequency of administration.
Since severe adverse reactions may occur even after administration of small doses, regular medical examinations are necessary. Your doctor should order tests to rule out abnormalities in blood parameters (e.g. low white blood cell count, low platelet count, lymphoma) and changes in the liver and kidneys.
You must inform your doctor immediately if any of the following symptoms occur in the patient, as they may indicate severe, potentially life-threatening adverse reactions requiring urgent treatment:

• sudden wheezing, difficulty breathing, swelling of the eyelids, face or lips, rash or itching (especially affecting the whole body)
• lung inflammation (symptoms may include general malaise, dry irritating cough, shortness of breath, breathlessness at rest, chest pain or fever)
• haemoptysis or coughing up blood-stained sputum
• severe skin peeling or formation of blisters on the skin
• unexplained bleeding (including vomiting blood) or appearance of bruises
• severe diarrhoea
• ulceration of the oral mucosa
• black or tarry stools
• blood in urine or faeces
• small red spots on the skin
• fever
• yellowing of the skin (jaundice)
• pain or difficulty urinating
• feeling of thirst and (or) frequent urination
• seizures (convulsions)
• loss of consciousness
• blurred vision or visual disturbances

The following adverse reactions have also been reported:
Very common (may occur in more than 1 in 10 people):

• loss of appetite
• nausea
• abdominal pain
• inflammation of the oral mucosa
• digestive disturbances
• increased liver enzyme activity.

Common (may occur in up to 1 in 10 people):

• decreased production of blood cells with reduced numbers of white and (or) red blood cells or platelets (leukopenia, anaemia, thrombocytopenia)
• headache
• feeling of fatigue
• drowsiness
• lung inflammation with dry cough, breathlessness and fever
• diarrhoea
• rash
• skin redness
• itching. Uncommon (may occur in up to 1 in 100 people):
• decreased number of blood cells and platelets
• dizziness
• disorientation
• depression
• oral ulceration
• vasculitis
• gastrointestinal ulceration and haemorrhage
• liver function disorders
• diabetes
• decreased blood protein levels
• urticaria
• photosensitivity
• fluid-filled blisters on the skin
• alopecia
• enlargement of rheumatoid nodules
• skin ulceration
• herpes zoster
• joint or muscle pain
• osteoporosis (reduced bone mass)
• inflammation and ulceration of the urinary bladder (may present with haematuria)
• kidney function disorders
• painful urination
• inflammation and ulceration of the vagina. Rare (may occur in up to 1 in 1000 people):
• infection (including reactivation of latent chronic infection)
• sepsis
• red eyes
• allergic reactions
• anaphylactic shock
• decreased level of antibodies in blood
• impaired ventricular filling due to fluid accumulation in the pericardium
• Pneumocystis jiroveci-induced pneumonia
• visual disturbances
• pericarditis
• fluid accumulation in the pericardial sac
• low blood pressure
• blood clots
• lung damage
• breathlessness
• bronchial asthma
• fluid accumulation in the pleural sac
• gingivitis
• acute hepatitis
• brownish skin discoloration
• acne
• presence of red or purple spots due to haemorrhages
• allergic vasculitis
• fever
• bone fractures
• kidney failure
• reduced or absence of urine production
• electrolyte disturbances
• slow wound healing. Very rare (may occur in up to 1 in 10,000 people):
• marked decrease in certain white blood cells (agranulocytosis)
• severe bone marrow failure
• liver failure
• lymph node swelling
• pain
• muscle weakness
• tingling and numbness/reduced sensitivity to stimuli
• taste disturbances (metallic taste in mouth)
• cramps
• inflammation of the membranes covering the brain, causing paralysis or vomiting
• deterioration of vision
• Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell's syndrome)
• nail discoloration
• retinal damage
• vomiting blood
• fever, sore throat, fatigue followed by skin damage
• loss of libido
• problems achieving erection
• infection of the nail fold of the hands
• severe gastrointestinal complications
• boils
• visible enlargement of small blood vessels
• hot flushes
• breast enlargement in men (gynaecomastia)
• lymphoproliferative disorders (excessive white blood cell proliferation)
• disturbances in semen production
• menstrual disorders.

Unknown (frequency cannot be estimated from available data):

• redness and peeling of the skin
• swelling
• tissue necrosis at the injection site
• increased number of certain white blood cells (eosinophilia)
• certain brain disorders (encephalopathy/leukoencephalopathy)
• nosebleeds
• pulmonary haemorrhage
• presence of protein in urine
• feeling of weakness
• jawbone damage (secondary to excessive white blood cell proliferation).

Subcutaneous administration of methotrexate is locally well tolerated. Only mild skin reactions (such as burning sensation, erythema, swelling, discolouration, intense itching, pain) have been observed after administration of Methotrexate EVER Pharma, which diminish during treatment.
Reporting of adverse reactions
If any adverse reactions occur, including any not listed in this leaflet, inform your doctor or pharmacist. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.
Reporting adverse reactions helps provide more information on the safety of the medicine.

5. How to store Methotrexate EVER Pharma

Keep this medicine out of sight and reach of children.
Do not store above 25°C.
Do not store in a refrigerator or freeze.
Store the pre-filled syringe in its outer packaging to protect from light.
Do not use this medicine after the expiry date stated on the label of the pre-filled syringe and the cardboard box: Expiry date (EXP). The expiry date refers to the last day of the stated month.
Do not use this medicine if the syringe is damaged or if the solution is not clear and contains particles.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What Methotrexate EVER Pharma contains

• The active substance is methotrexate. One mL of injection solution contains 25 mg of methotrexate.

Methotrexate EVER Pharma, 7.5 mg
Each pre-filled syringe with 0.3 mL of injection solution contains 7.5 mg of methotrexate.
Methotrexate EVER Pharma, 10 mg
Each pre-filled syringe with 0.4 mL of injection solution contains 10 mg of methotrexate.
Methotrexate EVER Pharma, 12.5 mg
Each pre-filled syringe with 0.5 mL of injection solution contains 12.5 mg of methotrexate.
Methotrexate EVER Pharma, 15 mg
Each pre-filled syringe with 0.6 mL of injection solution contains 15 mg of methotrexate.
Methotrexate EVER Pharma, 17.5 mg
Each pre-filled syringe with 0.7 mL of injection solution contains 17.5 mg of methotrexate.
Methotrexate EVER Pharma, 20 mg
Each pre-filled syringe with 0.8 mL of injection solution contains 20 mg of methotrexate.
Methotrexate EVER Pharma, 22.5 mg
Each pre-filled syringe with 0.9 mL of injection solution contains 22.5 mg of methotrexate.
Methotrexate EVER Pharma, 25 mg
Each pre-filled syringe with 1 mL of injection solution contains 25 mg of methotrexate.

• The other ingredients are sodium chloride, sodium hydroxide (for pH adjustment), hydrochloric acid (for pH adjustment) and water for injections.

What Methotrexate EVER Pharma looks like and contents of the pack
Methotrexate EVER Pharma is available in 1 mL pre-filled syringes made of colourless glass (Type I), with a fixed stainless steel needle, closed with a bromobutyl rubber stopper, and equipped with a needle safety system.
The pre-filled syringes are equipped with a safety system preventing needlestick injuries after use.
Packaged in PET foil blisters.
The following pack sizes are available, with syringes contained in a cardboard box:
1 pre-filled syringe in one blister
4 pre-filled syringes in two double blisters
12 pre-filled syringes in six double blisters
Not all pack sizes may be marketed.

Marketing Authorisation Holder
EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee
Austria

Manufacturer
EVER Pharma Jena GmbH
Otto-Schott-Strasse 15
07745 Jena
Germany

For any further information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
EVER Pharma Poland Sp. z o.o.
e-mail: [email protected]

This medicinal product is authorised in the European Economic Area countries under the following names:
Germany: Methotrexat EVER Pharma 7.5 mg, 10 mg, 12.5 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg Injektionslösung in einer Fertigspritze
Poland: Methotrexate EVER Pharma
Czech Republic: Methotrexát EVER Pharma
Slovakia: Metotrexát EVER Pharma 7.5 mg, 10 mg, 12.5 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg injekčný roztok v naplnenej injekčnej striekačke